Drug intelligence / Profile preview

[123I] AV 39

Development stage: Phase 1
Lead developer: Avid Radiopharmaceuticals
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[123I] AV 39 is a radiopharmaceutical imaging agent currently in Phase I development for the diagnosis of Alzheimer's disease. It is designed to be used with Single-Photon Emission Computed Tomography (SPECT) imaging to visualize and quantify protein disposition, specifically beta-amyloid plaques, in the brains of individuals with Alzheimer's disease. The drug is developed by Avid Radiopharmaceuticals, a company known for its work on amyloid imaging agents, which was later acquired by Eli Lilly and Company.

Other names: 123I AV39

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on [123I] AV 39.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [123I] AV 39.

Explore the full profile